The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib

Jing Zhang(Tongji University), Yan Pan(Anhui University)
Current Research in Pharmacology and Drug Discovery
January 1, 2025
Cited by 3


Related Papers